You were attending the BIO in San Diego ? Special discount for BIO attendees is extended. Register by July 18th and get 50% off the regular fee for the 2nd attendee to attend BioFIT event.

Please register with the promotional code: BIODISCOUNT

Register NOW

Mark Bradley Wilson, Partner at Fulbright & Jaworski LLP will chair 2 linked panel discussions on creative solutions to dealmaking problems and on how to best apply strategic alliance management.

Emerge and happen: creative solutions to difficult problems in dealmaking, on December 3rd, 11am

That things can go wrong in negotiations and partnership is not surprising. However, when you encounter these problems, sometimes creative solutions are needed in order to finally create a mutually beneficial partnership. During this interactive session, the panelists will discuss the common and no so common pitfalls in partnering and negotiations, as well as share their experience on the different stages of negotiations, the difficulties they ran into and the solutions they found.

Make it work and last: how to best apply strategic alliance management, on December 3rd, 2pm

The deal signature is just the beginning of a long road to travel for putting in place a successful partnership. The alliance management is an important piece of the puzzle and if well implemented and understood by both parties, it becomes an effective and invaluable tool in the management of the deal. Let’s discuss how to set it correctly on paper and how to identify the right key licensing terms to the deal and how to manage the partnership in an efficient and rewarding way for both parties.Come meet our speakers of these 2 sessions:

• Stepan LENSKY, Head Strategic Transactions & Alliance Management, BOEHRINGER INGELHEIM
• Juergen WALKENHORST, Head of Life Sciences, PROVENDIS GMBH
• Pascale REDIG, Senior Manager Research & Academic Partnerships / Member of ASTP-Proton Professional Development Committee, JANSSEN PHARMACEUTICA / ASTP PROTON

Mark B. WILSON’s biography

Mark Wilson is a partner in Austin, where his practice focuses on all aspects of patent prosecution and enforcement.

Mark’s docket is split among patent counseling, patent prosecution and patent litigation matters, with an emphasis in biotechnology related matters. Mr. Wilson has significant experience in the areas of genetic engineering, gene therapy, molecular biotechnology assays, chemotherapy, drug screening and targeting, animal and plant breeding programs, biomass production, renewable energy, clean energy technologies, organic chemistry, pharmaceutical development and medical devices.

Mark counsels clients regarding intellectual property portfolio development, management and commercialization on a global scale. He is experienced in technology transfer, including both licensing and company formation and funding. Mr. Wilson drafts and reviews licensing, confidentiality and material transfer agreements. He also prepares pre-litigation, infringement, validity, patentability and freedom-to-operate opinions and provides due diligence review of intellectual property to companies and investors.

Mark’s patent prosecution practice includes all aspects of drafting and prosecuting patent applications before the United States Patent and Trademark Office. He also supervises the prosecution of patent applications before many foreign patent offices. In addition, Mr. Wilson is experienced in appeal and interference practice before the Board of Patent Appeals and Interferences.

Mark’s litigation experience includes all phases of discovery and trial in federal district courts, including investigation and formulation of litigation strategy, motion practice, depositions, preparation and examination of witnesses, trials and evidentiary hearings. He has experience in briefing and the development of appellate strategy before the Court of Appeals for the Federal Circuit.

Mark is involved in a wide variety of professional activities. In 2012, he was elected as Deputy Secretary General of FICPI (Federation Internationale des Conseils en Propriete Industrielle), having previously served FICPI as the Assistant Reporter General of the CET. Mark is a frequent presenter at FICPI events and participant in FICPI delegations, visiting government IP offices around the world.

Dr. Adam STOTEN, Deputy Head of Technology Transfer at ISIS Innovation Ltd, the technology transfer company of the University of Oxford will be sharing his experiences in the following panel:

“Scouting innovation: academia push and industry pull” on december 3rd and 4pm

Academia wants to push out knowledge and innovation on the one hand and the industry is looking to pull it in and bring it to market on the other hand. However simple this might seem, when putting it into practice there are many challenges to overcome. Let’s find out which are the new models that pharma and biotech are using in scouting the innovation and how are TTOs better packaging the offer in order to find more matches with the demand?

Dr. Adam STOTEN’s biography

Adam joined Isis in the role of Deputy Head of Technology Transfer in 2013, with specific responsibility for commercialisation of life/medical science technologies originating from Oxford research. Adam has worked for more than a decade in the pharma/biotech sector in commercial roles encompassing business development and licensing, new venture formation, product development, lobbying/advocacy and general management. Between 2010 and 2013 Adam worked for Emergent BioSolutions Inc as Deputy General Manager for the Oxford-Emergent Tuberculosis Consortium Ltd, a joint venture with the University of Oxford which conducted the first ever efficacy study of a new TB vaccine in infants. Adam first worked at Isis between 2005 and 2010, successfully managing a wide range of licensing deals and spin-outs spanning therapeutics, vaccines, diagnostics, research tools and software. Prior to 2005 he worked as Head of Research for a specialist pharma/biotech consultancy undertaking due diligence and market research projects. Adam has a 1st Class Honours degree in biology and a PhD in immunology from the University of Nottingham.

Contact us to take part in this panel

Check full program

Current Partnering, the leading publisher of deal term reports within the life sciences.

Designed to translate research into commercial success, Current Partnering provides an opportunity for the dissemination of the latest trends in partnering activity across the life sciences.

Current Partnering report titles cover all aspects of partnering best practice and deal terms, providing users with the information and insight required to optimise their partnering activities.

Their reports cover all aspects of partnering best practice. Recent titles include:

• Companion Diagnostics Partnering Terms and Agreements
• Biomarker Partnering Terms and Agreements
• Partnering Agreements in Diagnostics
• Co-promotion and Co-marketing Agreements in Pharma and Biotech
• Merger and Acquisition Agreements in Pharma and Biotech
• Product and Asset Purchase Agreements in Pharma, Biotech and Diagnostics
• Option and Evaluation Agreements in Pharma and Biotech
• Royalty Financing Agreements in Pharma, Biotech and Diagnostics
• Practical Guide to Finding Partners in Pharma and Biotech
• Partnering Agreements with Big Pharma

Further details for each report can be viewed online.

Check full list of Supporters

Thank you for visiting the french pavillion and meeting the BioFIT team.

We hope you all enjoyed your stay in San Diego city and had successfull meetings at the BIO Convention.

The special discount for BIO attendees still stands. Register by the end of this week and you will receive 50% off the regular fee for the 2nd attendee at BioFIT event.

Please register with the promotional code: BIODISCOUNT

Register NOW

Heading to San Diego next week for the BIO Convention? We too !

Don’t forget to come by the french pavilion #2917, Nutrition Health and Longevity Cluster booth to get your DISCOUNT COUPON to attend BioFIT 2014 next December 2nd and 3rd.

Schedule a meeting with us and learn more on BioFIT opportunities for presenting and speaking !

Maximize your visibility at the exhibition area or become a sponsor of the event.

Become a sponsor

Present your technology or services

Share a panel discussion with international experts

Exhibition fees

 

BioFIT preliminary program is now available !

Discover attendees profiles, the conference agenda, a  speakers list and BioFIT hosted events.

Download the program

The first Scientific Committee Meeting for IDEA Summit was held last Tuesday June 11th in Lille. Experts in the field discussed latest trends and research results in the field, highlighting hot issues that must be discussed during the Summit next December 2nd and 3rd.

On the menu:

• a Partnering Convention with academia, biotech, pharma, biobanks, incubators, clusters, investors, policy makers
• Conferences and round tables to explore hands-on approaches to private/public collaborations among which Stratified Medicine, Translational research, Research Agenda…

About IDEA Summit

IDEA Summit is the unique event dedicated to translational research on diabetes in Europe. Key decision makers from academia and industry, and other stakeholders attend the meeting.

About the Scientific Committee

Its role is to define and steer the content of the conference program and contribute to the recruitment of speakers.

Members:

• Philippe FROGUEL, Director of UMR CNRS 8199, Pasteur Institute of Lille (FR) and Professor and Chair of Genomics of Common Disease, Imperial College London (UK)
• Mark PEAKMAN, Professor of Clinical Immunology, King’s College London – Immunobiology (UK)

• Mark WALKER, Professor of Molecular Diabetic Medicine, University of Newcastle (UK)

• Stefano DEL PRATO, Professor of Endocrinology and Metabolism at the School of Medicine, Chief of the Section of Diabetes, University of Pisa (IT)
• Leif GROOP, MD, PhD, Professor, Head of Unit, Lund University (SE)
• Marc DONATH, Professor at Endocrinology, Diabetes and Metabolism, University Hospital Basel (CH)

Learn more on IDEA SUMMIT

Register now and enjoy our Early Bird fees